ENDYMED Completes Strategic Merger for Enhanced Global Presence
ENDYMED Ltd is excited to announce a significant milestone: the full merger with its majority shareholder, Shanghai Haohai Biological Technology Co., Ltd. This merger signifies a robust evolution in ENDYMED's operational framework, promising to bolster its influence in the global market.
Transforming Market Dynamics
This alliance is designed to amplify ENDYMED's operational efficiency in the Chinese market and beyond, transforming its market presence. By uniting with Haohai, ENDYMED is set to optimize its resources, leading to a more competitive and efficient service offering.
A Unified Approach
With this merger, ENDYMED enjoys heightened strategic flexibility. The increased resources allow for enhanced decision-making that is supported by a unified operational structure. Such a framework means that ENDYMED can innovate more rapidly, streamline its supply chain, and solidify its standing in critical international regions.
Leadership Insights
Yossi Bar-On, CEO of ENDYMED, emphasized the merger's transformative impact. "This integration empowers us to serve our customers better across the globe, leveraging our combined expertise while retaining focus on local market needs. We are unlocking synergies that will enable us to offer faster and more effective solutions to our clients."
Building a Future of Innovation
Dr. Hou, Chairman of Haohai and ENDYMED, shared additional insights into the merger's potential, stating, "This strategic maneuver not only elevates our global standing but also enhances the holistic value we provide to our customers. Together, we can drive innovation and sustainable growth on a worldwide scale."
About Shanghai Haohai
Shanghai Haohai is at the forefront of biomedical material technology and genetic engineering, specializing in the development and commercialization of medical devices and pharmaceuticals. With a robust presence in the biopharmaceutical sector, it was notably listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange STAR Market, signifying its status as a pioneering company in China.
About ENDYMED's Offerings
ENDYMED positions itself as a leader in energy-based aesthetic treatment systems. Holding FDA clearance for its innovative 3DEEP RF technology, ENDYMED provides devices that are among the most clinically validated available, catering to both professional clinics and home users. Pioneering advancements in skin rejuvenation and wrinkle treatments, ENDYMED is committed to meeting the evolving needs of healthcare professionals and patients worldwide.
Frequently Asked Questions
What is the impact of the merger on ENDYMED's operations?
The merger is expected to enhance ENDYMED's operational efficiency and expand its market presence globally.
Who are the key executives mentioned in relation to the merger?
Yossi Bar-On, the CEO of ENDYMED, and Dr. Hou, Chairman of Haohai and ENDYMED, have articulated the merger's benefits.
What technologies does ENDYMED specialize in?
ENDYMED specializes in energy-based aesthetic treatment systems, focusing on skin rejuvenation and related treatments.
How does Shanghai Haohai contribute to the merger?
Shanghai Haohai offers strategic resources and expertise that complement ENDYMED's goals, aiding in innovative developments.
What is the future outlook for ENDYMED following the merger?
The merger positions ENDYMED to enhance its innovation capabilities and meet customer demands more effectively globally.
